<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002960'>Autoimmune diseases</z:hpo> are the consequence of the immune system attack on the self </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0002960'>Autoimmunity</z:hpo>, sometimes, is reflected through the production of autoantibodies to various self antigens leading to cellular malfunction or destruction </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study we employ such autoantibodies for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> originated from the respective <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="3" pm="."><plain>This concept is wide and entails many <z:hpo ids='HP_0002960'>autoimmune disorders</z:hpo> and diversity of malignant conditions </plain></SENT>
<SENT sid="4" pm="."><plain>To illustrate the therapeutic and practical potential we depicted four examples: <z:hpo ids='HP_0001045'>vitiligo</z:hpo> and <z:hpo ids='HP_0002861'>melanoma</z:hpo> - <z:hpo ids='HP_0001045'>vitiligo</z:hpo> is considered dermatologic <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> presented as depigmented skin areas </plain></SENT>
<SENT sid="5" pm="."><plain>The destruction of the pigmented cells (melanocytes) is mediated by autoantibodies </plain></SENT>
<SENT sid="6" pm="."><plain>We have purified these anti-melanocyte antibodies from patients with <z:hpo ids='HP_0001045'>vitiligo</z:hpo> and showed their cytotoxic effect towards <z:hpo ids='HP_0002861'>malignant melanoma</z:hpo> cells in vitro and in vivo; anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome (APLS) and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells differ from <z:mpath ids='MPATH_458'>normal</z:mpath> cells by the expression of phosphatydilserine (PS) on their outer membrane surface </plain></SENT>
<SENT sid="7" pm="."><plain>We have used such anti-PS autoantibodies, derived from patients with APLS, as effective treatment for <z:hpo ids='HP_0002861'>melanoma</z:hpo> in a murine system; <z:hpo ids='HP_0001890'>Autoimmune hemolytic anemia</z:hpo> (AIHA) and <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> - in patients with AIHA, the red blood cells (RBC) destruction is mediated by binding of autoantibodies to RBC </plain></SENT>
<SENT sid="8" pm="."><plain>We have shown the specific binding of these anti-RBC autoantibodies to RBC and to malignant cells of the erythroid lineage </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, these autoantibodies may have diagnostic/therapeutic potential for conditions such as <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> and <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera; anti-lymphocyte antibodies and <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> - in SLE and other systemic autoimmune conditions autoantibodies directed against lymphocytes can be found </plain></SENT>
<SENT sid="10" pm="."><plain>These cytotoxic antibodies can be targeted against lymphocytes of <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> such as <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, or <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>The diversity of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> provides a great source for human preformed highly specific autoantibodies which can be used as an effective immunotherapy by themselves, for diagnostic purposes, as a cell specific carrier conjugated to other cytotoxic agents and in combined therapy in the combat against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>